News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Western Blot analysis of extracts from C2C12 cells, cultured in the presence or absence of serum (O/N) and treated with or without AICAR (0.5 mM, 30 min), using Phospho-AMPKalpha (Thr172) (40H9) Rabbit mAb #2535.

Learn more about how we get our images
Image

Product Usage Information

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures. AICAR is supplied at 250 mM in water. Thaw completely before use. For a 0.5 mM working concentration, dilute 1:500. For a 2 mM working concentration, dilute 1:125. Treat cells with desired concentration for 5-60 minutes.

Please note: Appearance of AICAR solution should be a clear to yellow/brown solution without precipitation. If precipitation is observed, warm tightly capped vial at 37C until AICAR goes into solution. Agitation of warmed solution by vortex may be necessary.


Storage: Store solution at -20ºC. Protect from light. Use within 12 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

258.24 g/mol


Purity:

98%


Molecular Formula:

C9H14N4O5


AICAR (5-Aminoimidazole-4-carboxyamide ribonucleoside) is an adenosine analog taken up by muscle and phosphorylated to form 5-aminoimidazole-4-carboxamide-1--D-ribofuranosyl-5'-monophosphate (ZMP), which stimulates AMPK activity and glucose transport in skeletal muscle (1). AICAR has been used in studies measuring glucose uptake, diabetes and insulin resistance, and energy regulation during exercise. AICAR acts by entering nucleoside pools and significantly increasing levels of adenosine during periods of ATP breakdown (2).


1.  Sakoda, H. et al. (2002) Am. J. Physiol. Endocrinol. Metab. 282, E1239-E1244.

2.  Mullane, K. et al. (1993) Trends Cardiovasc. Med. 3, 227-234.

3.  Jakobsen, S. N. et al. (2001) J. Biol. Chem. 276, 46912-46916.

4.  Jessen, N. et al. (2003) J. Appl. Physiol. 94, 1373-1379.

5.  Giri, S. et al. (2004) J. Neurosci. 24, 479-487.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.